• Ulrich Schwabe
  • Thomas Rabe


Die wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und Kontrazeptiva. Danach folgen mit weitem Abstand Gestagene, AntiÖstrogene und Androgene.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arzneimittelkommission der Deutschen Ärzteschaft (2003): Rote Hand Brief zur Hormontherapie im Klimakterium vom 09.12.2003. Scholar
  2. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E et al (2000): Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34: 161–168.PubMedCrossRefGoogle Scholar
  3. Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, Cummings SR (2001): Effects of hormone replacement therapy on clinical fractures and height loss: the heart and estrogen/Progestin replacement study (HERS). Am J Med 110: 442–450.PubMedCrossRefGoogle Scholar
  4. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995): Estrogen replacement therapy and fractures in older women. Ann Intern Med 122: 9–16.PubMedGoogle Scholar
  5. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE et al (1995): The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589–1593.PubMedCrossRefGoogle Scholar
  6. Collaborative Group on Hormonal Factors in Breast Cancer (1997): Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047–1059.CrossRefGoogle Scholar
  7. Collaborative Study Group on the Desogestrel-containing Progesteron-only Pill (1998): A double blind study comparing the contraceptive efficacy, acceptability and safety of two progesteron-only pills containing desogestrel 75 micro-grams/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3: 169–178.CrossRefGoogle Scholar
  8. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999): Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645.PubMedCrossRefGoogle Scholar
  9. Fisher B, Constantino JP, Wickerham LD, Redmond CK et al (1998): Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer I 90: 1371–1388.CrossRefGoogle Scholar
  10. Grady D (2002): A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA 287: 2130–2137.PubMedCrossRefGoogle Scholar
  11. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933–1001.PubMedGoogle Scholar
  12. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE et al (2000): Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343: 522–529.PubMedCrossRefGoogle Scholar
  13. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998): Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613.PubMedCrossRefGoogle Scholar
  14. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593.PubMedCrossRefGoogle Scholar
  15. Katz S, Morales AJ (1998): Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause. Semin Reprod Endocrinol 16: 161–170.PubMedCrossRefGoogle Scholar
  16. Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323: 1–9.CrossRefGoogle Scholar
  17. König HJ (1991): Hirnkreislaufstörungen unter Einnahme gestodenhaltiger hormonaler oraler Kontrazeptiva — Kausalität oder Koinzidenz? Dtsch Ärztebl 91: C-1745–1748.Google Scholar
  18. Lamberts SW, van den Beld AW, van der Lely AJ (1997): The endocrinology of aging. Science 278: 419–424.PubMedCrossRefGoogle Scholar
  19. Manson JE, Martin KA (2001): Postmenopausal hormone-replacement therapy. N Engl J Med 345: 34–40.PubMedCrossRefGoogle Scholar
  20. Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427.CrossRefGoogle Scholar
  21. Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 87: 16–23.PubMedCrossRefGoogle Scholar
  22. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM et al (2001): Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 104: 499–503.Google Scholar
  23. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 283: 1007–1015.PubMedCrossRefGoogle Scholar
  24. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R (1995): Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, dros-pirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80: 1816–1821.PubMedCrossRefGoogle Scholar
  25. Powles T, Eeles R, Ashley S, Easton D, Chang J et al (1998): Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen randomised Chemoprevention Trial. Lancet 352: 98–101.PubMedGoogle Scholar
  26. Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546.Google Scholar
  27. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000): Menopausal estrogen and estsrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485–491.PubMedCrossRefGoogle Scholar
  28. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312: 83–88.PubMedCrossRefGoogle Scholar
  29. Tang M-X, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H (1996): Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348: 429–432.PubMedCrossRefGoogle Scholar
  30. Veronesi U, Maisonneuve P, Costa A, Saccini V Maltoni C et al on behalf of the Italian Tamoxifen Prevention Study (1998): Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial amoung hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352: 93–97.PubMedGoogle Scholar
  31. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588.Google Scholar
  32. Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712.CrossRefGoogle Scholar
  33. Writing Group for the Women’s Health Initiative (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  • Thomas Rabe
    • 2
  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelberg
  2. 2.Universitäts-FrauenklinikHeidelberg

Personalised recommendations